TNF and atopic eczema: Type II biomarkers have been identified for various psoriasis and atopic dermatitis therapies, including biomarkers representing Th17 pathway [33–35], monocyte activity (e.g. TNF-α) [31], lymphocyte activity (Granzyme B) and type I interferon pathways [16–24].